Peanut oral immunotherapy

DRUG6 trials

Sponsors

University of North Carolina, Chapel Hill, Cambridge University Hospitals NHS Foundation Trust, Guy's and St Thomas' NHS Foundation Trust, Massachusetts General Hospital, Philippe Bégin

Conditions

Food HypersensitivityPeanut AllergyPeanut Hypersensitivity

Phase 1

Peanut Oral Immunotherapy and Anti-Immunoglobulin E (IgE) for Peanut Allergy

CompletedNCT00932282

University of North Carolina, Chapel HillPeanut Hypersensitivity

Start: 2009-07-31End: 2015-08-31Updated: 2018-03-01

Study of Tolerance to Oral Peanut

CompletedNCT01259804

Cambridge University Hospitals NHS Foundation TrustPeanut Allergy

Start: 2008-01-31End: 2012-01-31Updated: 2015-01-14

Phase 2

Determining the Efficacy and Value of Immunotherapy on the Likelihood of Peanut Tolerance: The DEVIL Study

CompletedNCT00932828

University of North Carolina, Chapel HillFood Hypersensitivity

Start: 2009-06-22End: 2017-02-01Updated: 2018-05-24

Adjuvant Treatment With Abatacept to Promote Remission During Peanut Oral Immunotherapy

CompletedNCT04872218

Philippe BéginPeanut Allergy

Start: 2022-03-01End: 2024-11-04Updated: 2024-11-27

Unknown Phase

The Grown Up Peanut Immunotherapy Study

CompletedNCT03648320

Guy's and St Thomas' NHS Foundation TrustPeanut Allergy

Start: 2018-10-15End: 2022-05-19Updated: 2024-05-29

Food Oral Immunotherapy for Peanut Allergy

Active, not recruitingNCT04222491

Massachusetts General HospitalPeanut Allergy

Start: 2020-06-25End: 2026-12-01Target: 500Updated: 2026-04-09

Related Papers

Oral Immunotherapy in Peanut‐Allergic Adults Using Real‐World Materials

Allergy2025-04-233 citations

Abatacept to induce remission of peanut allergy during oral immunotherapy (ATARI): protocol for a phase 2a randomized controlled trial

Frontiers in Medicine2023-06-284 citations

Efficacy and safety of high-dose peanut oral immunotherapy with factors predicting outcome.

2011-03-18119 citations